DK0436252T3 - Farmaceutisk præparat til oral administration i flydende form - Google Patents

Farmaceutisk præparat til oral administration i flydende form

Info

Publication number
DK0436252T3
DK0436252T3 DK90203430.5T DK90203430T DK0436252T3 DK 0436252 T3 DK0436252 T3 DK 0436252T3 DK 90203430 T DK90203430 T DK 90203430T DK 0436252 T3 DK0436252 T3 DK 0436252T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
oral administration
liquid form
psychotropic
granules
Prior art date
Application number
DK90203430.5T
Other languages
Danish (da)
English (en)
Inventor
Gerrit Bernardus Maria Beuving
Henrik De Nijs
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of DK0436252T3 publication Critical patent/DK0436252T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK90203430.5T 1989-12-30 1990-12-19 Farmaceutisk præparat til oral administration i flydende form DK0436252T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL8903199 1989-12-30

Publications (1)

Publication Number Publication Date
DK0436252T3 true DK0436252T3 (da) 1993-12-27

Family

ID=19855853

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90203430.5T DK0436252T3 (da) 1989-12-30 1990-12-19 Farmaceutisk præparat til oral administration i flydende form

Country Status (14)

Country Link
US (1) US5238688A (fr)
EP (1) EP0436252B1 (fr)
JP (1) JP3051459B2 (fr)
KR (1) KR0156735B1 (fr)
AT (1) ATE93136T1 (fr)
AU (1) AU634614B2 (fr)
CA (1) CA2033418C (fr)
DE (1) DE69002822T2 (fr)
DK (1) DK0436252T3 (fr)
ES (1) ES2060001T3 (fr)
IE (1) IE63986B1 (fr)
NZ (1) NZ236626A (fr)
PT (1) PT96401B (fr)
ZA (1) ZA9010452B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
DE69913116T2 (de) * 1998-04-02 2004-06-03 Akzo Nobel N.V. Orale flüssige lösung enthaltend das antidepressivum mirtazapine
US6492320B2 (en) * 1999-09-24 2002-12-10 Rohm And Hass Company Multifunctional, granulated pellet aid and process
TWI256309B (en) * 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
AU780817B2 (en) * 2000-01-19 2005-04-21 Akzo Nobel N.V. Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
WO2003077842A2 (fr) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company Suspension orale de gout agreable et procede associe
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
EP1689371A2 (fr) * 2003-11-25 2006-08-16 Aurobindo Pharma Limited Compositions pharmaceutiques de mirtazapine
DE102004034043A1 (de) * 2004-07-13 2006-02-09 Krka Tovarna Zdravil, D.D. Feste pharmazeutische Zusammensetzung, die Mirtazapin enthält
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4128641A (en) * 1975-07-31 1978-12-05 Hzi Research Center Inc. Tetracyclic psychotropic drug
NL7809726A (nl) * 1978-09-26 1980-03-28 Akzo Nv Nieuwe tetracyclische verbindingen.
JPS5665825A (en) * 1979-10-31 1981-06-03 Mochida Pharmaceut Co Ltd Remedy for peptic ulcer
US4623588A (en) * 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
US4870060A (en) * 1985-03-15 1989-09-26 Janssen Pharmaceutica Derivatives of γ-cylodextrin
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
DE3775880D1 (fr) * 1986-09-18 1992-02-20 London School Of Pharmacy Innovations Ltd., London, Gb
DE3856555T2 (de) * 1987-10-16 2004-04-29 Elan Corp. Plc Diltiazem-Zusammensetzungen mit kontrollierter Wirkstoffabsorption
EP0319061A1 (fr) * 1987-11-28 1989-06-07 Akzo N.V. Médicament antiémétique

Also Published As

Publication number Publication date
CA2033418C (fr) 2002-05-14
NZ236626A (en) 1992-10-28
EP0436252B1 (fr) 1993-08-18
CA2033418A1 (fr) 1991-07-01
JP3051459B2 (ja) 2000-06-12
DE69002822T2 (de) 1993-12-23
DE69002822D1 (de) 1993-09-23
ZA9010452B (en) 1991-10-30
PT96401A (pt) 1991-10-15
KR0156735B1 (ko) 1998-11-16
US5238688A (en) 1993-08-24
EP0436252A1 (fr) 1991-07-10
IE904531A1 (en) 1991-07-03
PT96401B (pt) 1998-06-30
AU6839890A (en) 1991-07-04
JPH04210638A (ja) 1992-07-31
AU634614B2 (en) 1993-02-25
ATE93136T1 (de) 1993-09-15
KR910011266A (ko) 1991-08-07
ES2060001T3 (es) 1994-11-16
IE63986B1 (en) 1995-06-28

Similar Documents

Publication Publication Date Title
DK0436252T3 (da) Farmaceutisk præparat til oral administration i flydende form
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
IT1235532B (it) Composti carbossiammidici, procedimenti per la preparazione dei medesimi e composizione farmaceutica contenente i medesimi
ATE164080T1 (de) Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
DE69330672D1 (de) Pharmazeutische zubereitung zur anwendung in den atemwegen
MD1813C2 (ro) Derivaţi purificaţi de ciclodextrină ai eterilor sulfoalchilici sau amestecurile lor, complex clatrat al derivaţilor de ciclodextrină cu conţinut de medicament şi compoziţie farmaceutică
DE69034226D1 (de) Herstellungsverfahren von Huperzine A und deren Analogen und Verbindungen nützlich dazu
NO870560L (no) Nytt farmasoeytisk preparat.
ATE138590T1 (de) Pyrogensorbentmittel
SE8804628D0 (sv) New compounds
PT89802A (pt) Processo para a preparacao de uma composicao farmaceutica, contendo o factor xiii de coagulacao do sangue humano, para a prevencao da hemorragia intraventricular em criancas permaturas
PT90308A (pt) Processo para a preparacao de composicoes farmaceuticas contendo azelastina com libertacao controlada da substancia activa
SE8400723D0 (sv) Farmaceutisk komposition
IL95444A0 (en) (quinolin-2-yl-methoxy)phenylacetic acid derivatives containing cyclic substituents,their preparation and pharmaceutical compositions containing them
GR890100833A (en) Process for the preparation of a compound with gastric inhibitopy effect
DE3767894D1 (de) 1,2-dithiol-3-thion-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellung.
ATE65025T1 (de) Kalziumkarbonatsuspension enthaltende pharmazeutische zusammensetzung.
ATE119898T1 (de) Nmda-blockierende verbindungen, pharmazeutische präparate, deren herstellung und verwendung.
DK0450123T3 (da) Farmaceutisk præparat til topisk administration indeholdende dichlofenac-natrium
LV10917A (lv) Bambuterina pielietojums lipidu saturu pazeminosu farmaceitisku kompoziciju pagatavosanai
ES2150305T3 (es) Composicion anhidra a base de lactulosa.
SE8106498L (sv) Kvaternera salter av n,n3-di(beta-brompropionyl)-n1,n2-dispirotripiperazinium, forfarande for framstellning av desamma och lekemedelspreparat innehallande desamma
IT8720271A0 (it) Nuovi derivati dell'ergolene, composizioni farmaceutiche che licontengono e procedimento per lapreparazione dei medesimi.
ATE175870T1 (de) Pharmazeutische zubereitung zur rektalen verabreichung von pharmakologisch wirksamen verbindungen
IT1213568B (it) Derivati imidazolici adattivita' terapeutica, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.